The Europe Inhalation Capsules Market would witness market growth of 5.5% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Inhalation Capsules Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $83.5 Million by 2031. The UK market is exhibiting a CAGR of 4.5% during (2024 - 2031). Additionally, The France market would experience a CAGR of 6.3% during (2024 - 2031).
Inhalation capsules, also known as dry powder inhalers (DPIs), are devices used to deliver medication directly into the lungs as a dry powder. Typically employed to treat respiratory conditions, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma, these capsules contain a powdered formulation of the medication. As per the World Health Organization (WHO), COPD accounted for around 6% of all deaths in 2019 and ranks as the third leading cause of death. In addition, lower respiratory infections remained the deadliest communicable disease, ranked as the 4th leading cause of death.
Additionally, the inhalation mode of drug delivery entails the patient passing their breath through the apparatus, which subsequently distributes the powdered medication into the pulmonary system for absorption into the bloodstream. The purpose of inhalation capsules is to deliver medication to the respiratory system in a targeted and efficient manner. This method provides several benefits, including improved patient compliance, a quicker onset of action, and decreased systemic side effects.
Several factors drive the growth of the inhalation capsules market in various European nations. Countries like Germany, France, Italy, and the United Kingdom are witnessing significant growth in the inhalation capsules market due to the aging population, environmental factors, and lifestyle changes contributing to the rise in respiratory disorders. Thus, all these factors will boost the regional market’s expansion in the coming years.
Based on Type, the market is segmented into Gelatin Capsules, and Hypromellose Capsules. Based on Application, the market is segmented into Asthma Treatment, COPD Management, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Inhalation Capsules Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $83.5 Million by 2031. The UK market is exhibiting a CAGR of 4.5% during (2024 - 2031). Additionally, The France market would experience a CAGR of 6.3% during (2024 - 2031).
Inhalation capsules, also known as dry powder inhalers (DPIs), are devices used to deliver medication directly into the lungs as a dry powder. Typically employed to treat respiratory conditions, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma, these capsules contain a powdered formulation of the medication. As per the World Health Organization (WHO), COPD accounted for around 6% of all deaths in 2019 and ranks as the third leading cause of death. In addition, lower respiratory infections remained the deadliest communicable disease, ranked as the 4th leading cause of death.
Additionally, the inhalation mode of drug delivery entails the patient passing their breath through the apparatus, which subsequently distributes the powdered medication into the pulmonary system for absorption into the bloodstream. The purpose of inhalation capsules is to deliver medication to the respiratory system in a targeted and efficient manner. This method provides several benefits, including improved patient compliance, a quicker onset of action, and decreased systemic side effects.
Several factors drive the growth of the inhalation capsules market in various European nations. Countries like Germany, France, Italy, and the United Kingdom are witnessing significant growth in the inhalation capsules market due to the aging population, environmental factors, and lifestyle changes contributing to the rise in respiratory disorders. Thus, all these factors will boost the regional market’s expansion in the coming years.
Based on Type, the market is segmented into Gelatin Capsules, and Hypromellose Capsules. Based on Application, the market is segmented into Asthma Treatment, COPD Management, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Cipla Limited
- Novartis AG
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Lonza Group Ltd. (Capsugel)
- Chiesi Farmaceutici S.p.A
- Vectura Group Plc (Philip Morris International, Inc.)
- Elpen S.A.
- Healthcaps India Ltd.
- Qualicaps Co., LTD. (Roquette Freres SA)
Market Report Segmentation
By Type- Gelatin Capsules
- Hypromellose Capsules
- Asthma Treatment
- COPD Management
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Europe Inhalation Capsules Market by Type
Chapter 6. Europe Inhalation Capsules Market by Application
Chapter 7. Europe Inhalation Capsules Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Cipla Limited
- Novartis AG
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Lonza Group Ltd. (Capsugel)
- Chiesi Farmaceutici S.p.A
- Vectura Group Plc (Philip Morris International, Inc.)
- Elpen S.A.
- Healthcaps India Ltd.
- Qualicaps Co., LTD. (Roquette Freres SA)
Methodology
LOADING...
